Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) – Equities research analysts at Oppenheimer Holdings dropped their FY2016 earnings per share estimates for Eiger BioPharmaceuticals in a research report issued on Tuesday. Oppenheimer Holdings analyst J. Olson now anticipates that the firm will earn ($7.66) per share for the year, down from their prior forecast of ($7.41). Oppenheimer Holdings also issued estimates for Eiger BioPharmaceuticals’ Q4 2016 earnings at ($1.39) EPS, FY2017 earnings at ($5.36) EPS, FY2018 earnings at ($5.14) EPS, FY2019 earnings at ($5.43) EPS and FY2020 earnings at ($3.53) EPS.

Several other equities research analysts have also issued reports on EIGR. Zacks Investment Research raised Eiger BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 18th. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Eiger BioPharmaceuticals in a report on Thursday, August 11th. Finally, Jefferies Group reissued a “buy” rating and issued a $33.00 price objective on shares of Eiger BioPharmaceuticals in a report on Thursday, October 20th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $34.00.

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at 13.50 on Friday. The firm has a 50-day moving average price of $12.67 and a 200-day moving average price of $17.15. Eiger BioPharmaceuticals has a 52 week low of $10.71 and a 52 week high of $28.35. The stock’s market capitalization is $112.81 million.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.70.

In related news, insider James P. Shaffer bought 3,125 shares of Eiger BioPharmaceuticals stock in a transaction on Thursday, August 18th. The stock was acquired at an average price of $15.70 per share, with a total value of $49,062.50. Following the acquisition, the insider now directly owns 5,620 shares of the company’s stock, valued at $88,234. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Fund Vi L.P. Vivo bought 187,500 shares of Eiger BioPharmaceuticals stock in a transaction on Thursday, August 18th. The shares were bought at an average cost of $16.00 per share, with a total value of $3,000,000.00. The disclosure for this purchase can be found here. 27.20% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of EIGR. Teachers Advisors Inc. bought a new position in Eiger BioPharmaceuticals during the second quarter worth $108,000. California State Teachers Retirement System raised its position in Eiger BioPharmaceuticals by 20.7% in the third quarter. California State Teachers Retirement System now owns 8,762 shares of the company’s stock worth $117,000 after buying an additional 1,500 shares during the last quarter. Bank of New York Mellon Corp raised its position in Eiger BioPharmaceuticals by 14.3% in the third quarter. Bank of New York Mellon Corp now owns 12,319 shares of the company’s stock worth $165,000 after buying an additional 1,541 shares during the last quarter. BlackRock Investment Management LLC raised its position in Eiger BioPharmaceuticals by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 12,459 shares of the company’s stock worth $167,000 after buying an additional 104 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in Eiger BioPharmaceuticals during the third quarter worth $169,000. 37.82% of the stock is owned by institutional investors and hedge funds.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

5 Day Chart for NASDAQ:EIGR

Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.